309pdoes Administration Order of Sequential Fec- Docetaxel as Adjuvant Chemotherapy for Breast Cancer Affect on the Toxicities? : a Retrospective Analysis from a Single-center.

نویسندگان

  • T Miyaki
  • H Tsujimura
  • K Kumagai
  • R Nakamura
  • A Yoshii
  • Y Okubo
  • T Iwase
  • A Nakagawa
  • N Yamamoto
چکیده

Aim: Anthracyclines and taxanes based regimens have been established as one of standard adjuvant chemotherapy for early breast cancer. For the high-risk patients, sequential rather than the concomitant use of both agents should be considered. Conventionally, Anthracyclines followed by taxanes (AT) are preferred. However, some recent trials reported that preceding taxanes had equivalent efficacy. Since each has different toxic profile, it is important to compare AT with TA in terms of toxicity and relative dose intensity (RDI). The purpose of this retrospective study was to assess the influence of administration order.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Incidence of taxane-induced pain and distress in patients receiving chemotherapy for early-stage breast cancer: a retrospective, outcomes-based survey.

INTRODUCTION With the widespread use of sequential anthracycline/taxane-based chemotherapy for early-stage breast cancer, clinicians are becoming rapidly aware of toxicities associated with those regimens. Despite the low incidence reported in the literature of significant arthralgia and myalgia with those regimens, it is clinically evident that a substantial proportion of patients develop such...

متن کامل

The SUCCESS-C trial: Interim analysis of toxicity evaluating the role of an anthracycline-free chemotherapy regimen in the adjuvant treatment of HER2/neu-negative breast cancer.

1070 Background: Taxane-based anthracycline containing chemotherapy has been established as treatment option in the adjuvant setting of early breast cancer. Indication was recently enlarged for high risk node negative breast cancer. Promising retrospective data indicate equi-efficacy of anthracycline-free chemotherapy in Her2/neu-negative patients (Gennari et al., Slamon et al.). Anthracycline-...

متن کامل

Quercetin Synergistically Enhances the Anticancer Efficacy of Docetaxel through Induction of Apoptosis and Modulation of PI3K/AKT, MAPK/ERK, and JAK/STAT3 Signaling Pathways in MDA-MB-231 Breast Cancer Cell Line

Docetaxel is widely used in the treatment of metastatic breast cancer. However, its effectiveness is limited due to chemoresistance and its undesirable side effects. The combination of chemotherapeutic agents and natural compounds is an effective strategy to overcome drug resistance and the ensuing inevitable toxicities. Quercetin is a natural flavonoid with strong antioxidant and anticancer ac...

متن کامل

Sequential adjuvant docetaxel and anthracycline chemotherapy for node positive breast cancers: a retrospective study.

PURPOSE Anthracyclines and taxanes are the most active agents in the adjuvant treatment of breast cancer (BC). They can be used simultaneously or sequentially. The optimal schedule and duration for their administration is unknown. We analyzed the efficacy of sequential adjuvant anthracycline and docetaxel administration in node positive BC patients. METHODS Node positive BC patients (N=539) f...

متن کامل

Adjuvant chemotherapy for luminal A breast cancer: a prospective study comparing two popular chemotherapy regimens

INTRODUCTION Based on the variable benefit of taxanes in the adjuvant setting of early breast cancer in certain tumor phenotypes, especially in human epidermal growth factor receptor (HER)2-positive and triple-negative disease, and with the observation of a lesser benefit in luminal A, this research article aimed at exploring the value of docetaxel in patients with an estrogen receptor-positive...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Annals of oncology : official journal of the European Society for Medical Oncology

دوره 25 suppl_4  شماره 

صفحات  -

تاریخ انتشار 2014